1
|
Martin L, Chapusot C, Tarris G, Remond A, Millière A, Pioche C, Dubois J, Laffage N, Aubry M, Dubois LM, Andrianiaina H, Provost N, Funes de la Vega M, Grangier N, Harizay F, Douchet C, Tournier B, Guibert C, Aubriot-Lorton MH. [Contribution of connected prescriptions (NetSIG) for the management of molecular pathology exams]. Ann Pathol 2024:S0242-6498(24)00050-6. [PMID: 38503611 DOI: 10.1016/j.annpat.2024.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 01/10/2024] [Accepted: 02/13/2024] [Indexed: 03/21/2024]
Abstract
INTRODUCTION This study describes our experience implementing a connected prescription software (NetSIG, Terascop) for molecular pathology exams. MATERIAL AND METHODS NetSIG was set up for liquid biopsies and tissue testing. After registration and activation of regional pathology laboratories, NetSIG was implemented for external then internal prescriptions. RESULTS NetSIG allows users to follow up on all prescriptions on the website, to interact through messages and to consult reports after validation. External set up was quick (3-4 months) and comprehensive (>70%). Prescriptions were made by physicians or more often by secretaries or referring pathologists. Internal prescriptions were made by pathologists then registered in NetSIG by our secretaries. This deployment strategy has resulted in very good completeness of prescriptions (>90%). DISCUSSION AND CONCLUSION Connected prescriptions made this complex circuit more fluid and facilitated the redistribution of different administrative and technical tasks. The number of phone calls decreased sharply. Half of the prescriptions were made by pathologists and half by oncologists (physicians or secretaries). The mean dearchiving duration for blocks was one day. Mean forwarding of blocks was 2.5 days. Mean turnaround time was 8 days for targeted techniques and 13 days for Next Generation Sequencing. Physicians appreciated the interactivity of the software and the fact that they could consult it on a smartphone.
Collapse
Affiliation(s)
- Laurent Martin
- Service de pathologie, CHU de Dijon, Dijon, France; Plateforme de génétique somatique des cancers de Bourgogne, CHU de Dijon, Dijon, France.
| | - Caroline Chapusot
- Service de pathologie, CHU de Dijon, Dijon, France; Plateforme de génétique somatique des cancers de Bourgogne, CHU de Dijon, Dijon, France
| | | | - Alicia Remond
- Service de pathologie, CHU de Dijon, Dijon, France; Plateforme de génétique somatique des cancers de Bourgogne, CHU de Dijon, Dijon, France
| | | | - Célia Pioche
- Service de pathologie, CHU de Dijon, Dijon, France; Plateforme de génétique somatique des cancers de Bourgogne, CHU de Dijon, Dijon, France
| | | | | | - Manon Aubry
- Service de pathologie, CHU de Dijon, Dijon, France; Plateforme de génétique somatique des cancers de Bourgogne, CHU de Dijon, Dijon, France
| | - Lyse Marie Dubois
- Service de pathologie, CHU de Dijon, Dijon, France; Plateforme de génétique somatique des cancers de Bourgogne, CHU de Dijon, Dijon, France
| | | | | | | | - Nadège Grangier
- Service de pathologie, CHU de Dijon, Dijon, France; Plateforme de génétique somatique des cancers de Bourgogne, CHU de Dijon, Dijon, France
| | - Fara Harizay
- Service de pathologie, CHU de Dijon, Dijon, France
| | | | - Benjamin Tournier
- Service de pathologie, CHU de Dijon, Dijon, France; Plateforme de génétique somatique des cancers de Bourgogne, CHU de Dijon, Dijon, France
| | | | - Marie Hélène Aubriot-Lorton
- Service de pathologie, CHU de Dijon, Dijon, France; Plateforme de génétique somatique des cancers de Bourgogne, CHU de Dijon, Dijon, France
| |
Collapse
|
2
|
Lv W, Cheng H, Shao D, Wei Y, Zhu W, Wu K, Jiang W, Hu L, Sha Z, Zhong B, Pei X. Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China. Front Oncol 2021; 11:630717. [PMID: 33777783 PMCID: PMC7988081 DOI: 10.3389/fonc.2021.630717] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 01/04/2021] [Indexed: 12/30/2022] Open
Abstract
Although the National Comprehensive Cancer Network and the Chinese Society of Clinical Oncology guidelines recommend comprehensive genomic profiling of lung adenocarcinoma, it has not been widely applied in Chinese hospitals. This observational study aimed to determine real-world evidence of whether comprehensive genomic profiling can benefit the survival of patients with lung cancer. We investigated the frequency of genomic alterations, treatment strategies, and clinical outcomes in 233 patients with advanced non-small cell lung carcinoma who were routinely screened using a 508-gene panel. The most prevalent drivers were mutations of EGFR (51%), KRAS (9%), PIK3CA (7%), ALK (7%), MET (6%), and BRAF (5%). Mutations in tumor suppressor genes included TP53, KEAP1, RB1, PTEN, and APC. Median overall survival (OS) was significantly shorter among patients harboring KRAS (mutant, n = 17; WT, n = 154) and TP53 (mutant, n = 103; WT n =68) mutations (11.3 vs. 24.0 months; P = 0.16 and 18.7 vs. 28.7 months; P = 0.018, respectively). The OS was longer among patients with tumors harboring EGFR (P = 0.069) and ALK (P = 0.51) mutations. Most patients (65.4%) with the driver gene-positive (EGFR, ALK, and ROS1) tumors were received TKI treatment, whereas those with driver gene wild tumors (53.1%) chose platinum-based therapy. Univariate and multivariate analyses associated a shorter OS among patients with tumors harboring concomitant TP53 and EGFR mutations. These findings provide additional evidence from real-world on the potential importance of targeted therapies as a treatment option in NSCLC patients harboring clinically actionable mutation.
Collapse
Affiliation(s)
- Weize Lv
- Department of Interventional Medicine, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.,Guangdong Provincial Key Laboratory of Biomedical Imaging, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
| | - Hua Cheng
- Guangdong Provincial Key Laboratory of Biomedical Imaging, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.,Department of Cardiothoracic Surgery, Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, China
| | - Di Shao
- BGI Genomics, BGI-Shenzhen, Shenzhen, China
| | - Yajun Wei
- Department of Interventional Medicine, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.,Guangdong Provincial Key Laboratory of Biomedical Imaging, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
| | - Weiping Zhu
- Department of Nephrology, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
| | - Kui Wu
- BGI-Shenzhen, Shenzhen, China
| | | | - Liyang Hu
- Guangdong Provincial Key Laboratory of Biomedical Imaging, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.,Department of Thoracic Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
| | - Zhou Sha
- Guangdong Provincial Key Laboratory of Biomedical Imaging, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.,Department of Thoracic Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
| | - Beilong Zhong
- Guangdong Provincial Key Laboratory of Biomedical Imaging, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.,Department of Cardiothoracic Surgery, Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, China
| | - Xiaofeng Pei
- Guangdong Provincial Key Laboratory of Biomedical Imaging, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.,Department of Thoracic Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
| |
Collapse
|
3
|
Tsang ES, Shen Y, Chooback N, Ho C, Jones M, Renouf DJ, Lim H, Sun S, Yip S, Pleasance E, Ionescu DN, Mungall K, Kasaian K, Ma Y, Zhao Y, Mungall A, Moore R, Jones SJM, Marra M, Laskin J. Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer. Cold Spring Harb Mol Case Stud 2019; 5:a002659. [PMID: 30514790 PMCID: PMC6371742 DOI: 10.1101/mcs.a002659] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Accepted: 11/05/2018] [Indexed: 12/19/2022] Open
Abstract
The Personalized Onco-Genomics (POG) program at BC Cancer integrates whole-genome (DNA) and RNA sequencing into practice for metastatic malignancies. We examined the subgroup of patients with metastatic non-small-cell lung cancer (NSCLC) and report the prevalence of actionable targets, treatments, and outcomes. We identified patients who were enrolled in the POG program between 2012 and 2016 who had a tumor biopsy and blood samples with comprehensive DNA (80×, 40× normal) and RNA sequencing followed by in-depth bioinformatics to identify potential cancer drivers and actionable targets. In NSCLC cases, we compared the progression-free survival (PFS) of "POG-informed therapies" with the PFS of the last regimen prior to POG (PFS ratio). In 29 NSCLC cases, 11 were male (38%), the median age was 60.2 yr (range: 39.4-72.6), and histologies included were adenocarcinoma (93%) and squamous cell carcinoma (7%). Potential molecular targets (i.e., cancer drivers including TP53 mutations) were identified in 26 (90%), and 21 (72%) had actionable targets. Therapies based on standard-of-care mutation analysis, such as EGFR mutations, were not considered POG-informed therapies. Thirteen received POG-informed therapies, of which three had no therapy before POG; therefore a comparator PFS could not be obtained. Of 10 patients with POG-informed therapy, median PFS ratio was 0.94 (IQR 0.2-3.4). Three (30%) had a PFS ratio ≥1.3, and three (30%) had a PFS ratio ≥0.8 and <1.3. In this small cohort of NSCLC, 30% demonstrated longer PFS with POG-informed therapies. Larger studies will help clarify the role of whole-genome analysis in clinical practice.
Collapse
Affiliation(s)
- Erica S Tsang
- Division of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Yaoqing Shen
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Negar Chooback
- Division of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Cheryl Ho
- Division of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Martin Jones
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Daniel J Renouf
- Division of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Howard Lim
- Division of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Sophie Sun
- Division of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Stephen Yip
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - Erin Pleasance
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Diana N Ionescu
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - Karen Mungall
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Katayoon Kasaian
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Yussanne Ma
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Yongjun Zhao
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Andrew Mungall
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Richard Moore
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Steven J M Jones
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| | - Marco Marra
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
- Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - Janessa Laskin
- Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada
| |
Collapse
|
4
|
High-throughput detection of clinically targetable alterations using next-generation sequencing. Oncotarget 2018; 8:40345-40358. [PMID: 28404952 PMCID: PMC5522202 DOI: 10.18632/oncotarget.15875] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Accepted: 01/23/2017] [Indexed: 12/17/2022] Open
Abstract
Next-generation sequencing (NGS) has revolutionized the therapeutic care of patients by allowing high-throughput and parallel sequencing of large numbers of genes in a single run. However, most of available commercialized cancer panels target a large number of mutations that do not have direct therapeutic implications and that are not fully adapted to low quality formalin-fixed, paraffin-embedded (FFPE) samples. Here, we designed an amplicon-based NGS panel assay of 16 currently actionable genes according to the most recent recommendations of the French National Cancer Institute (NCI). We developed a panel of short amplicons (<150 bp) using dual-strand library preparation. The clinical validation of this panel was performed on well-characterized controls and 140 routine diagnostic samples, including highly degraded and cross-linked genomic DNA extracted from FFPE tumor samples. All mutations were detected with elevated inter-laboratory and inter-run reproducibility. Importantly, we could detect clinically actionable alterations in FFPE samples with variant allele frequencies as low as 1%. In addition, the overall molecular diagnosis rate was increased from 40.7% with conventional techniques to 59.2% with our NGS panel, including 41 novel actionable alterations normally not explored by conventional techniques. Taken together, we believe that this new actionable target panel represents a relevant, highly scalable and robust tool that is easy to implement and is fully adapted to daily clinical practice in hospital and academic laboratories.
Collapse
|
5
|
Ilie M, Butori C, Lassalle S, Heeke S, Piton N, Sabourin JC, Tanga V, Washetine K, Long-Mira E, Maitre P, Yazbeck N, Bordone O, Lespinet V, Leroy S, Cohen C, Mouroux J, Marquette CH, Hofman V, Hofman P. Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. Oncotarget 2017; 8:103055-103062. [PMID: 29262544 PMCID: PMC5732710 DOI: 10.18632/oncotarget.21476] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 09/19/2017] [Indexed: 01/26/2023] Open
Abstract
Treatment with EGFR inhibitors is limited to patients with advanced/metastatic non-small cell lung cancer who have known EGFR mutations. Currently, patient care has to respond to several imperatives to make these inhibitors broadly available to all patients; fast and accurate detection of EGFR mutations by a sensitive and specific standardized cost-effective method, easy-to-implement in settings with limited expertise in molecular diagnostics. We evaluated the Idylla™ EGFR Mutation Assay (Biocartis) for the detection of EGFR mutations in archived formalin-fixed paraffin-embedded (FFPE) tumor samples from a series of 55 patients with lung adenocarcinoma and compared these results with those obtained by a pyrosequencing ISO-15189 accredited laboratory method. The comparison was made on both whole surgical tumor sections and on three artificially constructed small biopsies (∼1 mm) from the same FFPE blocks. Cost-effectiveness and turnaround time comparison between the two methods was performed. On both whole tissue sections and on biopsy cores, the Idylla™ and pyrosequencing had an agreement of 95% (52/55). The Idylla™ EGFR Assay produced results faster and more cost-effective than pyrosequencing. The Idylla™ system showed a good sensitivity and was cost-saving in our setting. Because of the easy workflow, the Idylla™ system has the potential to expand EGFR testing to more pathology laboratories in a reliable and fast manner.
Collapse
Affiliation(s)
- Marius Ilie
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
- IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Catherine Butori
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Sandra Lassalle
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
- IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Simon Heeke
- IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Nicolas Piton
- Department of Pathology, Rouen University Hospital, Rouen, France
| | | | - Virginie Tanga
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Kevin Washetine
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Elodie Long-Mira
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
- IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Priscilla Maitre
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Nathalie Yazbeck
- IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Olivier Bordone
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Virginie Lespinet
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Sylvie Leroy
- Department of Pulmonary Medicine and Thoracic Oncology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Charlotte Cohen
- Department of Thoracic Surgery, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Jérôme Mouroux
- IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
- Department of Thoracic Surgery, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Charles Hugo Marquette
- IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
- Department of Pulmonary Medicine and Thoracic Oncology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Véronique Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
- IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| | - Paul Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
- IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
- Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
| |
Collapse
|
6
|
Gobbini E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, Di Maio M, Rossi G, Gregorc V, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, Catino A, Maiello E, Arizio F, Novello S. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. Lung Cancer 2017; 111:30-37. [DOI: 10.1016/j.lungcan.2017.06.009] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2017] [Revised: 06/14/2017] [Accepted: 06/15/2017] [Indexed: 10/19/2022]
|
7
|
Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, Ghiringhelli F, Fumoleau P, Spielmann M, Delaloge S, Poillot ML, Arveux P, Goubar A, Andre F, Zitvogel L, Kroemer G. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy 2016; 11:1878-90. [PMID: 26506894 DOI: 10.1080/15548627.2015.1082022] [Citation(s) in RCA: 79] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
In spite of adjuvant chemotherapy, a significant fraction of patients with localized breast cancer (BC) relapse after optimal treatment. We determined the occurrence of cytoplasmic MAP1LC3B/LC3B (microtubule-associated protein 1 light chain 3B)-positive puncta, as well as the presence of nuclear HMGB1 (high mobility group box 1) in cancer cells within surgical BC specimens by immunohistochemistry, first in a test cohort (152 patients) and then in a validation cohort of localized BC patients who all received adjuvant anthracycline-based chemotherapy (1646 patients). Cytoplasmic LC3B(+) puncta inversely correlated with the intensity of SQSTM1 staining, suggesting that a high percentage cells of LC3B(+) puncta reflects increased autophagic flux. After setting optimal thresholds in the test cohort, cytoplasmic LC3B(+) puncta and nuclear HMGB1 were scored as positive in 27.2% and 28.6% of the tumors, respectively, in the validation cohort, while 8.7% were considered as double positive. LC3B(+) puncta or HMGB1 expression alone did not constitute independent prognostic factors for metastasis-free survival (MFS) in multivariate analyses. However, the combined positivity for LC3B(+) puncta and nuclear HMGB1 constituted an independent prognostic factor significantly associated with prolonged MFS (hazard ratio: 0.49 95% confidence interval [0.26-0.89]; P = 0.02), and improved breast cancer specific survival (hazard ratio: 0.21 95% confidence interval [0.05-0.85]; P = 0.029). Subgroup analyses revealed that within patients with poor-prognosis BC, HMGB1(+) LC3B(+) double-positive tumors had a better prognosis than BC that lacked one or both of these markers. Altogether, these results suggest that the combined positivity for LC3B(+) puncta and nuclear HMGB1 is a positive predictor for longer BC survival.
Collapse
Affiliation(s)
- Sylvain Ladoire
- a Department of Medical Oncology, Georges François Leclerc Center ; Dijon , France.,b Institut National de la Santé et de la Recherche Médicale; U1015, Equipe labellisée Ligue Nationale Contre le Cancer; Institut Gustave Roussy , Villejuif , France
| | - Frédérique Penault-Llorca
- c Centre Jean Perrin, EA 4677 Clermont-Ferrand ; Clermont-Ferrand , France.,d ERTICa; EA 4677 University of Auvergne ; Clermont-Ferrand , France
| | - Laura Senovilla
- e Equipe 11 labellisée pas la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris , France.,f Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif , France
| | - Cécile Dalban
- g Biostatistics and Epidemiology Unit; EA 4184; Centre Georges Francois Leclerc Dijon , France
| | - David Enot
- f Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif , France
| | - Clara Locher
- b Institut National de la Santé et de la Recherche Médicale; U1015, Equipe labellisée Ligue Nationale Contre le Cancer; Institut Gustave Roussy , Villejuif , France
| | - Nicole Prada
- b Institut National de la Santé et de la Recherche Médicale; U1015, Equipe labellisée Ligue Nationale Contre le Cancer; Institut Gustave Roussy , Villejuif , France
| | - Vichnou Poirier-Colame
- b Institut National de la Santé et de la Recherche Médicale; U1015, Equipe labellisée Ligue Nationale Contre le Cancer; Institut Gustave Roussy , Villejuif , France
| | - Kariman Chaba
- e Equipe 11 labellisée pas la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris , France.,h Université Paris Descartes; Sorbonne Paris Cité ; Paris , France
| | - Laurent Arnould
- i Department of Pathology and Tumor Biology; Georges François Leclerc Center ; Dijon , France
| | - François Ghiringhelli
- a Department of Medical Oncology, Georges François Leclerc Center ; Dijon , France.,j Institut National de la Santé et de la Recherche Médicale; Avenir Team INSERM; CRI-866 University of Burgundy , Dijon , France
| | - Pierre Fumoleau
- a Department of Medical Oncology, Georges François Leclerc Center ; Dijon , France
| | - Marc Spielmann
- k Department of Medical Oncology and Breast Cancer Group; Institut Gustave Roussy , Villejuif , France
| | - Suzette Delaloge
- k Department of Medical Oncology and Breast Cancer Group; Institut Gustave Roussy , Villejuif , France
| | - Marie Laure Poillot
- g Biostatistics and Epidemiology Unit; EA 4184; Centre Georges Francois Leclerc Dijon , France
| | - Patrick Arveux
- g Biostatistics and Epidemiology Unit; EA 4184; Centre Georges Francois Leclerc Dijon , France
| | - Aicha Goubar
- l INSERM U981 "Identification of molecular predictors and new targets for cancer treatment"; Institut Gustave Roussy ; Villejuif , France
| | - Fabrice Andre
- k Department of Medical Oncology and Breast Cancer Group; Institut Gustave Roussy , Villejuif , France.,l INSERM U981 "Identification of molecular predictors and new targets for cancer treatment"; Institut Gustave Roussy ; Villejuif , France
| | - Laurence Zitvogel
- b Institut National de la Santé et de la Recherche Médicale; U1015, Equipe labellisée Ligue Nationale Contre le Cancer; Institut Gustave Roussy , Villejuif , France.,m University of Paris Sud XI , Villejuif , France.,n Center of Clinical Investigations in Biotherapies of Cancer (CICBT) , Villejuif , France
| | - Guido Kroemer
- f Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif , France.,o Pôle de Biologie; Hôpital Européen Georges Pompidou; Assistance Publique-Hôpitaux de Paris ; Paris , France.,p INSERM; U1138 , Paris , France
| |
Collapse
|
8
|
Siu LL, Conley BA, Boerner S, LoRusso PM. Next-Generation Sequencing to Guide Clinical Trials. Clin Cancer Res 2016; 21:4536-44. [PMID: 26473189 DOI: 10.1158/1078-0432.ccr-14-3215] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Rapidly accruing knowledge of the mutational landscape of malignant neoplasms, the increasing facility of massively parallel genomic sequencing, and the availability of drugs targeting many "driver" molecular abnormalities have spurred the oncologic community to consider how to use these new tools to improve cancer treatment. In order to assure that assignment of patients to a particular targeted treatment is likely to be beneficial to the patient, it will be necessary to conduct appropriate clinical research. It is clear that clinical (histology and stage) eligibility criteria are not sufficient for most clinical trials using agents that target mutations that are present in only a minority of patients. Recently, several clinical trial designs have been suggested to test the benefit of targeted treatment in molecular and/or clinical subgroups of patients. However, challenges remain in the implementation of such trials, including choice of assay, levels of evidence regarding gene variants, tumor heterogeneity, identifying resistance mechanisms, the necessity of screening large numbers of patients, infrastructure needs, and collaboration of investigators and industry. This article reviews current trial designs and discusses some of the considerations, advantages, and drawbacks of designing clinical trials that depend on particular molecular variants as eligibility criteria.
Collapse
Affiliation(s)
- Lillian L Siu
- Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
| | - Barbara A Conley
- Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland
| | - Scott Boerner
- Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
| | | |
Collapse
|
9
|
Cesuroglu T, Syurina E, Feron F, Krumeich A. Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature. BMJ Open 2016; 6:e010243. [PMID: 27412099 PMCID: PMC4947721 DOI: 10.1136/bmjopen-2015-010243] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
OBJECTIVES Various terms and definitions are used to describe personalised approaches to medicine and healthcare, but in ambiguous and inconsistent ways. They mostly have been defined in a top-down manner. However, actual practices might take different paths. Here, we aimed to provide a 'practice-based' perspective on the debate by analysing the content of 'personalised' practices published in the literature. METHODS The search in PubMed and EMBASE (April 2014) using the terms frequently used for personalised approaches resulted in 5333 records. 2 independent researchers used different strategies for screening, resulting in 157 articles describing 88 'personalised' practices that were implemented/presented on at least 1 individual/patient case. The content analysis was grounded on these data and did not have a priori analytical frameworks. RESULTS 'Personalised medicine/healthcare' can be a commodity in the healthcare market, a way how health services are provided, or a keyword for emerging applications. It can help individuals/patients to gain control of their health, health professionals to provide better services, healthcare organisations to increase effectiveness and efficiency, or national health systems to increase performance. Country examples indicated that for integration of practices into health services, attitude towards innovations and health system and policy context is important. Categorisation based on the terms or the technologies used, if any, was not possible. CONCLUSIONS This study is the first to provide a comprehensive content analysis of the 'personalised' practices in the literature. Unlike the top-down definitions, our findings highlighted not the technologies but real-life issues faced by the practices. 'Personalised medicine' and 'personalised healthcare' can be differentiated by using the former for specific tools available and the latter for health services with a holistic approach, implemented in certain contexts. To realise integration of 'personalised medicine/healthcare' into real life, science, technology, health policy and practice, and society domains must work together.
Collapse
Affiliation(s)
- Tomris Cesuroglu
- Faculty of Health, Medicine and Life Sciences, Department of Social Medicine, Maastricht University, Maastricht, The Netherlands
| | - Elena Syurina
- Faculty of Health, Medicine and Life Sciences, Department of Health, Ethics and Society, Maastricht University, Maastricht, The Netherlands Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | - Frans Feron
- Faculty of Health, Medicine and Life Sciences, Department of Social Medicine, Maastricht University, Maastricht, The Netherlands
| | - Anja Krumeich
- Faculty of Health, Medicine and Life Sciences, Department of Health, Ethics and Society, Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
10
|
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016; 387:1415-1426. [PMID: 26777916 DOI: 10.1016/s0140-6736(16)00004-0] [Citation(s) in RCA: 639] [Impact Index Per Article: 79.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. Nationally, however, the feasibility and effects on outcomes of this policy are unknown. We aimed to assess the characteristics, molecular profiles, and clinical outcomes of patients who were screened during a 1-year period by a nationwide programme funded by the French National Cancer Institute. METHODS This study included patients with advanced NSCLC, who were routinely screened for EGFR mutations, ALK rearrangements, as well as HER2 (ERBB2), KRAS, BRAF, and PIK3CA mutations by 28 certified regional genetics centres in France. Patients were assessed consecutively during a 1-year period from April, 2012, to April, 2013. We measured the frequency of molecular alterations in the six routinely screened genes, the turnaround time in obtaining molecular results, and patients' clinical outcomes. This study is registered with ClinicalTrials.gov, number NCT01700582. FINDINGS 18,679 molecular analyses of 17,664 patients with NSCLC were done (of patients with known data, median age was 64·5 years [range 18-98], 65% were men, 81% were smokers or former smokers, and 76% had adenocarcinoma). The median interval between the initiation of analysis and provision of the written report was 11 days (IQR 7-16). A genetic alteration was recorded in about 50% of the analyses; EGFR mutations were reported in 1947 (11%) of 17,706 analyses for which data were available, HER2 mutations in 98 (1%) of 11,723, KRAS mutations in 4894 (29%) of 17,001, BRAF mutations in 262 (2%) of 13,906, and PIK3CA mutations in 252 (2%) of 10,678; ALK rearrangements were reported in 388 (5%) of 8134 analyses. The median duration of follow-up at the time of analysis was 24·9 months (95% CI 24·8-25·0). The presence of a genetic alteration affected first-line treatment for 4176 (51%) of 8147 patients and was associated with a significant improvement in the proportion of patients achieving an overall response in first-line treatment (37% [95% CI 34·7-38·2] for presence of a genetic alteration vs 33% [29·5-35·6] for absence of a genetic alteration; p=0·03) and in second-line treatment (17% [15·0-18·8] vs 9% [6·7-11·9]; p<0·0001). Presence of a genetic alteration was also associated with improved first-line progression-free survival (10·0 months [95% CI 9·2-10·7] vs 7·1 months [6·1-7·9]; p<0·0001) and overall survival (16·5 months [15·0-18·3] vs 11·8 months [10·1-13·5]; p<0·0001) compared with absence of a genetic alteration. INTERPRETATION Routine nationwide molecular profiling of patients with advanced NSCLC is feasible. The frequency of genetic alterations, acceptable turnaround times in obtaining analysis results, and the clinical advantage provided by detection of a genetic alteration suggest that this policy provides a clinical benefit. FUNDING French National Cancer Institute (INCa).
Collapse
Affiliation(s)
- Fabrice Barlesi
- Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Centre d'Investigation Clinique, Marseille, France.
| | - Julien Mazieres
- Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier, Toulouse, France
| | - Jean-Philippe Merlio
- Centre Hospitalier Universitaire de Bordeaux, Pôle Biologie et Anatomie Pathologique, Pessac, France; Université de Bordeaux, Histologie et Pathologie Moléculaires des Tumeurs, Bordeaux, France
| | | | - Jean Mosser
- Centre Hospitalier Universitaire de Rennes, Département de Génomique et Génétique Moléculaire, Plateforme INCA, Rennes, France
| | - Hervé Lena
- Hôpital Pontchaillou, Service de Pneumologie, Centre Hospitalier Universitaire, Rennes, France
| | - L'Houcine Ouafik
- Assistance Publique Hôpitaux de Marseille, Service de Transfert d'Oncologie Biologique, Aix Marseille University, Marseille, France
| | - Benjamin Besse
- Gustave Roussy, Cancer Campus, Villejuif, France; University Paris-Sud, Châtenay-Malabry, France
| | - Isabelle Rouquette
- Institut Universitaire du Cancer de Toulouse, Oncopôle, Service d'Anatomie Pathologique, Toulouse, France
| | - Virginie Westeel
- Université de Franche-Comté, EA3181, Centre Hospitalier Universitaire Jean Minjoz, Service de Pneumologie, Besançon, France
| | - Fabienne Escande
- Centre Hospitalier Universitaire de Lille, Département de Biochimie et Biologie Moléculaire, Centre de Biologie Pathologie, Lille, France
| | - Isabelle Monnet
- Centre Hospitalier Intercommunal de Créteil, Service de Pneumologie et de Pathologie Professionnelle, Créteil, France
| | - Antoinette Lemoine
- Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier des Hôpitaux Universitaires Paris-Sud, Service d'Oncogénétique- Oncomolpath, Université Paris 11, Villejuif, France
| | - Rémi Veillon
- Centre Hospitalier Universitaire de Bordeaux, Service des Maladies Respiratoires, Pessac, France
| | - Hélène Blons
- UMR-S1147, INSERM, Université Paris Descartes, Assistance Publique Hôpitaux de Paris Département de Biologie, Hôpital Européen Georges Pompidou, Paris, France
| | | | - Pierre-Paul Bringuier
- Hôpital Edouard Herriot, Service d'Anatomie et de Cytologie Pathologique, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon Cancer Research Center, UMR 1057 INSERM, Lyon, France
| | - Régine Lamy
- Centre Hospitalier de Bretagne Sud, Service d'Oncologie Médicale, Lorient, France
| | - Michèle Beau-Faller
- Centre Hospitalier Universitaire de Hautepierre, Laboratoire de Biochimie et de Biologie Moléculaire & Plate-forme de Génomique des Cancers, Strasbourg, France
| | - Jean-Louis Pujol
- Centre Hospitalier Universitaire de Montpellier, Unité d'Oncologie Thoracique, Pôle Cœur Poumon, Hôpital Arnaud de Villeneuve, Montpellier, France
| | - Jean-Christophe Sabourin
- Centre Hospitalier Universitaire de Rouen, Département d'Anatomie et de Cytologie Pathologiques, Rouen, France
| | | | - Marc G Denis
- Centre Hospitalier Universitaire de Nantes, Laboratoire de Biochimie, Nantes, France
| | - Sylvie Lantuejoul
- Centre Hospitalier Universitaire A Michallon, Département d'Anatomie et Cytologie Pathologiques DACP, Institut de Biologie et de Pathologie, Université Joseph Fourier-INSERM U 823, Institut Albert Bonniot, Grenoble, France
| | - Franck Morin
- Clinical Research Unit, French Cooperative Thoracic Intergroup (IFCT), Paris, France
| | - Quân Tran
- Clinical Research Unit, French Cooperative Thoracic Intergroup (IFCT), Paris, France
| | - Pascale Missy
- Clinical Research Unit, French Cooperative Thoracic Intergroup (IFCT), Paris, France
| | - Alexandra Langlais
- Biostatistics Unit, French Cooperative Thoracic Intergroup (IFCT), Paris, France
| | - Bernard Milleron
- Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Service de Pneumologie, Sorbonne Universités, UPMC Université Paris 06, Paris, France
| | - Jacques Cadranel
- Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Service de Pneumologie, Sorbonne Universités, UPMC Université Paris 06, Paris, France
| | - Jean-Charles Soria
- Gustave Roussy, Cancer Campus, Villejuif, France; University Paris-Sud, Châtenay-Malabry, France
| | - Gérard Zalcman
- Centre Hospitalier Universitaire de Caen, Service de Pneumologie et Oncologie Thoracique, Centre de Recherche Clinique, Université de Caen-Basse Normandie, Caen, France
| |
Collapse
|
11
|
Sager M, Yeat NC, Pajaro-Van der Stadt S, Lin C, Ren Q, Lin J. Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization. Expert Rev Mol Diagn 2015; 15:1589-603. [PMID: 26565429 DOI: 10.1586/14737159.2015.1105133] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Transcriptomic technologies are evolving to diagnose cancer earlier and more accurately to provide greater predictive and prognostic utility to oncologists and patients. Digital techniques such as RNA sequencing are replacing still-imaging techniques to provide more detailed analysis of the transcriptome and aberrant expression that causes oncogenesis, while companion diagnostics are developing to determine the likely effectiveness of targeted treatments. This article examines recent advancements in molecular profiling research and technology as applied to cancer diagnosis, clinical applications and predictions for the future of personalized medicine in oncology.
Collapse
Affiliation(s)
- Monica Sager
- a College of Arts and Sciences , Washington University in St. Louis , St. Louis , MO , USA.,b Rare Genomics Institute , Bethesda , MD , USA
| | - Nai Chien Yeat
- b Rare Genomics Institute , Bethesda , MD , USA.,c School of Medicine , Washington University in St. Louis , St. Louis , MO , USA
| | - Stefan Pajaro-Van der Stadt
- a College of Arts and Sciences , Washington University in St. Louis , St. Louis , MO , USA.,b Rare Genomics Institute , Bethesda , MD , USA
| | - Charlotte Lin
- b Rare Genomics Institute , Bethesda , MD , USA.,c School of Medicine , Washington University in St. Louis , St. Louis , MO , USA
| | - Qiuyin Ren
- b Rare Genomics Institute , Bethesda , MD , USA.,d Whiting School of Engineering , Johns Hopkins University , Baltimore , MD , USA
| | - Jimmy Lin
- b Rare Genomics Institute , Bethesda , MD , USA
| |
Collapse
|
12
|
Parker D, Belaud-Rotureau MA. Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment. CLINICAL MEDICINE INSIGHTS-ONCOLOGY 2014; 8:145-52. [PMID: 25520569 PMCID: PMC4260793 DOI: 10.4137/cmo.s19236] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Revised: 10/12/2014] [Accepted: 10/20/2014] [Indexed: 11/30/2022]
Abstract
Break-apart fluorescence in situ hybridization (FISH) is the gold standard test for anaplastic lymphoma kinase (ALK) gene rearrangement. However, this methodology often is assumed to be expensive and potentially cost-prohibitive given the low prevalence of ALK-positive non-small cell lung cancer (NSCLC) cases. To more accurately estimate the cost of ALK testing by FISH, we developed a micro-cost model that accounts for all cost elements of the assay, including laboratory reagents, supplies, capital equipment, technical and pathologist labor, and the acquisition cost of the commercial test and associated reagent kits and controls. By applying a set of real-world base-case parameter values, we determined that the cost of a single ALK break-apart FISH test result is $278.01. Sensitivity analysis on the parameters of batch size, testing efficiency, and the cost of the commercial diagnostic testing products revealed that the cost per result is highly sensitive to batch size, but much less so to efficiency or product cost. This implies that ALK testing by FISH will be most cost effective when performed in high-volume centers. Our results indicate that testing cost may not be the primary determinant of crizotinib (Xalkori®) treatment cost effectiveness, and suggest that testing cost is an insufficient reason to limit the use of FISH testing for ALK rearrangement.
Collapse
Affiliation(s)
| | - Marc-Antoine Belaud-Rotureau
- Université de Rennes 1, Faculté de Médecine, Rennes, France. ; Service de Cytogénétique et Biologie Cellulaire, CHU de Rennes, Rennes, France. ; UMR 6290 IGDR, Cancer du Rein-BIOSIT, Rennes, France
| |
Collapse
|
13
|
Abstract
PURPOSE OF REVIEW Technical advances and progresses in tumor biology hold promise for the advent of new anticancer agents. These changes are impacting the conduct and design of clinical trials. This review describes the changing landscape of clinical research in metastatic breast cancer (MBC). RECENT FINDINGS Clinical trials in breast cancer that started between 2007 and 2011 were analyzed. In the metastatic setting, 72% (n = 479) of these studies evaluated targeted therapies and 21% (n = 139) conventional treatments. During this period, the number of phase II trials decreased over time, whereas biology-driven studies, although small in terms of absolute number, now represent 15% of the total. Nevertheless, genomic segments are too rare to allow conventional drug development and require changes in the way clinical trials are being done. Several options are being explored to address this challenge: develop large consortium, perform molecular screening in larger populations, develop clinical trials testing algorithm for treatment decision, and no longer drugs. SUMMARY The landscape of clinical research in MBC is changing with the development of molecular medicine. Research institutions and cooperative groups will need to adapt to this changing landscape in clinical research.
Collapse
|
14
|
|
15
|
Lacroix L, Boichard A, André F, Soria JC. Genomes in the clinic: the Gustave Roussy Cancer Center experience. Curr Opin Genet Dev 2014; 24:99-106. [DOI: 10.1016/j.gde.2013.11.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2013] [Accepted: 11/17/2013] [Indexed: 10/25/2022]
|
16
|
Andre F, Vicier C, Delaloge S. The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification? Am Soc Clin Oncol Educ Book 2014:e5-e10. [PMID: 24857146 DOI: 10.14694/edbook_am.2014.34.e5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Genomic studies have shown that breast cancer includes a large number of targetable genomic alterations. Most of these genomic alterations are rare and can evolve during the natural history of the disease. Three paths are being followed to develop precision medicine in metastatic breast cancer. First, the conventional path will consist of fragmenting the disease and developing drugs in each rare genomic segment. This will require screening large numbers of patients for genomic alterations to run the therapeutic trials, especially the registration trials. The second path will consist in clustering rare genomic alterations in more frequent segments defined by an altered pathway. Finally, one possible path for precision medicine will be to test genomic algorithms for the whole patient population with metastatic breast cancer. This latter scenario would reunify breast cancer into a single entity and test whether the use of genomics would improve outcomes in this population of patients. Challenges and perspective in the field of precision medicine will include the prediction of resistance, the integration of immunology, and DNA repair in the genomic algorithms and the transfer of concepts to early-stage breast cancers.
Collapse
Affiliation(s)
- Fabrice Andre
- From the Department of Medical Oncology and INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France; Department of Medical Oncology, Centre Paoli-Calmettes, Marseille, France
| | - Cecile Vicier
- From the Department of Medical Oncology and INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France; Department of Medical Oncology, Centre Paoli-Calmettes, Marseille, France
| | - Suzette Delaloge
- From the Department of Medical Oncology and INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France; Department of Medical Oncology, Centre Paoli-Calmettes, Marseille, France
| |
Collapse
|
17
|
Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol 2014; 232:121-33. [PMID: 24114583 PMCID: PMC4285848 DOI: 10.1002/path.4275] [Citation(s) in RCA: 73] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2013] [Revised: 09/17/2013] [Accepted: 09/21/2013] [Indexed: 01/02/2023]
Abstract
EGFR gene mutations and ALK gene fusions are well-characterized molecular targets in NSCLC. Activating alterations in a variety of potential oncogenic driver genes have also been identified in NSCLC, including ROS1, RET, MET, HER2, and BRAF. Together with EGFR and ALK, these mutations account for ∼20% of NSCLCs. The identification of these oncogenic drivers has led to the design of rationally targeted therapies that have produced superior clinical outcomes in tumours harbouring these mutations. Many patients, however, have de novo or acquired resistance to these therapies. In addition, most NSCLCs are genetically complex tumours harbouring multiple potential activating events. For these patients, disease subsets are likely to be defined by combination strategies involving a number of targeted agents. These targets include FGFR1, PTEN, MET, MEK, PD-1/PD-L1, and NaPi2b. In light of the myriad new biomarkers and targeted agents, multiplex testing strategies will be invaluable in identifying the appropriate patients for each therapy and enabling targeted agents to be channelled to the patients most likely to gain benefit. The challenge now is how best to interpret the results of these genomic tests, in the context of other clinical data, to optimize treatment choices in NSCLC.
Collapse
Affiliation(s)
| | - Ignacio I Wistuba
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer CenterHouston, Texas, USA
| |
Collapse
|
18
|
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2013; 21:69-78. [PMID: 23811849 DOI: 10.1038/cdd.2013.72] [Citation(s) in RCA: 172] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Revised: 05/06/2013] [Accepted: 05/27/2013] [Indexed: 12/22/2022] Open
Abstract
Immunogenic cell death induced by anticancer chemotherapy is characterized by a series of molecular hallmarks that include the exodus of high-mobility group box 1 protein (HMGB1) from dying cells. HMGB1 is a nuclear nonhistone chromatin-binding protein. It is secreted at the late stages of cellular demise and engages Toll-like receptor4 (TLR4) on dendritic cells (DCs) to accelerate the processing of phagocytic cargo in the DC and to facilitate antigen presentation by DC to T cells. The absence of HMGB1 expression by dying tumor cells exposed to anthracyclines or oxaliplatin compromises DC-dependent T-cell priming by tumor-associated antigens. Here, we show that transplantable tumors exhibiting weak expression of nuclear HMGB1 respond to chemotherapy more effectively if the treatment is combined with the local or systemic administration of a highly purified and physiochemically defined and standardized lipopolysaccharide solution, which acts as a high-potency and exclusive TLR4 agonist, called Dendrophilin (DEN). The synergistic antitumor effects mediated by the combination of chemotherapy and immunotherapy relied upon the presence of the MyD88 (myeloid differentiation primary response gene) adapter of TLR4 (but not that of the TIR-domain-containing adapter-inducing interferon-β adapter), in line with the well-characterized action of DEN on the MyD88 signaling pathway. DEN and anthracyclines synergized to induce intratumoral accumulation of interferon-γ-producing CD4(+) and CD8(+) T lymphocytes. Moreover, DEN could restore the immunogenicity of dying tumor cells from which HMGB1 had been depleted by RNA interference. These findings underscore the potential clinical utility of combination regimens involving immunogenic chemotherapy and certain TLR4 agonists in advanced HMGB1-deficient cancers.
Collapse
|
19
|
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes. Lung 2013; 191:491-9. [PMID: 23749122 DOI: 10.1007/s00408-013-9482-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2013] [Accepted: 05/15/2013] [Indexed: 10/26/2022]
Abstract
BACKGROUND Epidermal growth factor receptor (EGFR)-targeting therapies dramatically modified the prognosis of stage 4 non-small-cell lung cancer. Sensitizing EGFR mutations are the best efficacy factor of these treatments. In 2006, the French National Cancer Institute launched a network of 28 centers for EGFR molecular analysis in routine practice. The aim of this retrospective study was to describe the results of routine EGFR analysis in one of these centers (Lyon University Hospital) and to assess outcomes in patients with the mutation. METHODS EGFR mutations were analyzed for exons 18-21 by direct sequencing. The characteristics of each sample were retrospectively collected from the lab archives. Subsequent outcomes for patients harboring at least one mutation were retrospectively collected from each referring physician. RESULTS During 1 year, 792 samples were analyzed, corresponding to 753 patients. A total of 133 mutations were diagnosed in 124 samples (15.7 %), corresponding to 121 patients. Most of them (77.4 %) were sensitizing mutations and were located in exons 19 and 21. Others were resistance mutations (8.3 %) or rare mutations (14.3 %) for which effects on tyrosine kinase inhibitor (TKI) sensitivity are unknown. The rate of indeterminate results (i.e., no sequencing of the entire exon 19 or 21) was 6.3 % (n = 50 samples). The only factor statistically associated with a risk of failure was sample from bone tissue: 13.7 % gave incomplete results (i.e., no whole sequencing of exons 18-21). CONCLUSIONS Eighty-five of the 121 patients with EGFR mutations were treated with TKI. There were no differences in progression free survival (PFS) according to the type of molecule (erlotinib or gefitinib) or to the line of prescription of TKI. By contrast, exon 18 sensitizing mutations showed a worse PFS than exon 19 or 21 mutations. Finally, dose reduction was significantly more frequent in the erlotinib group than in the gefitinib group.
Collapse
|
20
|
André F, Ciccolini J, Spano JP, Penault-Llorca F, Mounier N, Freyer G, Blay JY, Milano G. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics 2013; 14:931-9. [DOI: 10.2217/pgs.13.79] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Current advances in the biology of cancer and emergence of new tools for genome analysis have opened clinical perspectives in oncology, generally termed as ‘personalized medicine’. This broad term must encompass previous well-proven strategies, such as pharmacogenetics- and pharmacokinetics-based dosing, with more recently introduced pharmacogenomics approaches, all applied as a means to tailor treatment to a given patient presenting with a given tumor. Despite outstanding results in lung cancer, colorectal cancer and melanoma, only a few predictive biomarkers are currently justified in routine clinical practice. Overall, there is a persistent gap between the growing number of identified deregulated pathways or genetic mutations, both at the tumor and the constitutional levels, and their actual implementation at the bedside as part of clinical routine. This article underlines these limitations and covers several issues that may explain the discrepancy between the plethora of published data about emerging biomarkers, and the relative scarcity of tests eventually reaching a clinically validated application. The main identified difficulties concern invasive and costly prospective biomarker studies and the issue of tumor heterogeneity. Finally, early trial designs for targeted therapies as well as those for conventional cytotoxics may not necessarily address the right questions by skipping critical end points. Proposed solutions point out the use of liquid biopsies and systems biology approaches, for an easier implementation of personalized medicine at the bedside.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Gérard Milano
- Centre Antoine Lacassagne, 33 Avenue de Valombrose – 06189, Nice Cedex, France
| |
Collapse
|
21
|
Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31:1039-49. [PMID: 23401433 PMCID: PMC3589700 DOI: 10.1200/jco.2012.45.3753] [Citation(s) in RCA: 357] [Impact Index Per Article: 32.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Substantial advances have been made in understanding critical molecular and cellular mechanisms driving tumor initiation, maintenance, and progression in non-small-cell lung cancer (NSCLC). Over the last decade, these findings have led to the discovery of a variety of novel drug targets and the development of new treatment strategies. Already, the standard of care for patients with advanced-stage NSCLC is shifting from selecting therapy empirically based on a patient's clinicopathologic features to using biomarker-driven treatment algorithms based on the molecular profile of a patient's tumor. This approach is currently best exemplified by treating patients with NSCLC with first-line tyrosine kinase inhibitors when their cancers harbor gain-of-function hotspot mutations in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene rearrangements. These genotype-based targeted therapies represent the first step toward personalizing NSCLC therapy. Recent technology advances in multiplex genotyping and high-throughput genomic profiling by next-generation sequencing technologies now offer the possibility of rapidly and comprehensively interrogating the cancer genome of individual patients from small tumor biopsies. This advance provides the basis for categorizing molecular-defined subsets of patients with NSCLC in whom a growing list of novel molecularly targeted therapeutics are clinically evaluable and additional novel drug targets can be discovered. Increasingly, practicing oncologists are facing the challenge of determining how to select, interpret, and apply these new genetic and genomic assays. This review summarizes the evolution, early success, current status, challenges, and opportunities for clinical application of genotyping and genomic tests in therapeutic decision making for NSCLC.
Collapse
Affiliation(s)
- Tianhong Li
- University of California Davis Comprehensive Cancer Center, Division of Hematology and Oncology, Sacramento, CA 95817, USA.
| | | | | | | |
Collapse
|
22
|
Jennings J, Hudson TJ. Reflections on the Founding of the International Cancer Genome Consortium. Clin Chem 2013; 59:18-21. [DOI: 10.1373/clinchem.2012.184713] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Jennifer Jennings
- ICGC Secretariat, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Thomas J Hudson
- ICGC Secretariat, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Departments of Molecular Genetics and
- Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
23
|
Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt S, Jessup JM. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 2012; 18:1515-23. [PMID: 22422403 PMCID: PMC3307147 DOI: 10.1158/1078-0432.ccr-11-2206] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Molecular diagnostics are becoming increasingly important in clinical research to stratify or identify molecularly profiled patient cohorts for targeted therapies, to modify the dose of a therapeutic, and to assess early response to therapy or monitor patients. Molecular diagnostics can also be used to identify the pharmacogenetic risk of adverse drug reactions. The articles in this CCR Focus section on molecular diagnosis describe the development and use of markers to guide medical decisions regarding cancer patients. They define sources of preanalytic variability that need to be minimized, as well as the regulatory and financial challenges involved in developing diagnostics and integrating them into clinical practice. They also outline a National Cancer Institute program to assist diagnostic development. Molecular diagnostic clinical tests require rigor in their development and clinical validation, with sensitivity, specificity, and validity comparable to those required for the development of therapeutics. These diagnostics must be offered at a realistic cost that reflects both their clinical value and the costs associated with their development. When genome-sequencing technologies move into the clinic, they must be integrated with and traceable to current technology because they may identify more efficient and accurate approaches to drug development. In addition, regulators may define progressive drug approval for companion diagnostics that requires further evidence regarding efficacy and safety before full approval can be achieved. One way to accomplish this is to emphasize phase IV postmarketing, hypothesis-driven clinical trials with biological characterization that would permit an accurate definition of the association of low-prevalence gene alterations with toxicity or response in large cohorts.
Collapse
Affiliation(s)
- George Poste
- Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University, 1475 North Scottsdale Road, Suite 361 Scottsdale, Arizona 85257
| | - David P. Carbone
- Professor of Medicine and Cancer Biology, Director, Thoracic/Head and Neck Program and Thoracic Oncology Center, Vanderbilt-Ingram Cancer Center, 691 Preston Building, Nashville, TN 37232-6838
| | - David R. Parkinson
- Chief Executive Officer, Nodality, Inc., 201 Gateway Boulevard, South San Francisco, CA 94080
| | - Jaap Verweij
- Chairman, Dept. of Medical Oncology and Daniel den Hoed Cancer Center, Erasmus University Medical Center, PO Box 2040, 3000 CA ROTTERDAM, Netherlands
| | - Stephen Hewitt
- Director, Tissue Array Research Program (TARP), Laboratory of Pathology, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD
| | - J. Milburn Jessup
- Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
| |
Collapse
|